摘要
目的研究孟鲁司特钠联合布地奈德对哮喘患儿疗效、呼吸指标及用药安全性的影响。方法将2016年5月至2018年4月于该院接受诊治的哮喘患儿120例作为观察对象,将其按照随机抽签法均分成试验组与参照组。参照组予以布地奈德治疗,试验组则在布地奈德治疗的基础上加用孟鲁司特钠治疗。对比两组疗效、治疗前后呼吸指标、不良反应发生情况以及血清炎症因子水平变化情况。结果试验组与参照组在总有效率方面对比,前者更高(P<0.05)。治疗后试验组与参照组在用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC水平方面对比,前者更高(均P<0.05)。试验组与参照组在口干、恶心、眩晕及嗜睡发生率方面对比差异无统计学意义(均P>0.05)。治疗后试验组与参照组在血清白细胞介素-4(IL-4)、白细胞介素-5(IL-5)水平方面对比,前者更低(均P<0.05)。结论孟鲁司特钠与布地奈德联合应用于哮喘患儿疗效显著,有效改善患儿呼吸指标水平,且用药安全性较好,有利于缓解炎症反应。
【Objective】To study the effect of montelukast sodium combined with budesonide on the efficacy,respiratory index and drug safety of children with asthma.【Methods】One hundred and twenty children with asthma who were diagnosed and treated in our hospital from May 2016 to April 2018 were selected as the observation objects and divided into experimental group and reference group according to the random lottery method.The control group was treated with budesonide,while the experimental group was treated with montelukast sodium on the basis of budesonide treatment.The efficacy of the two groups,respiratory indexes before and after treatment,adverse reactions and changes in serum inflammatory factors were compared.【Results】The total effective rate of the experimental group was higher than that of the control group(P<0.05).The levels of FVC,FEV1 and FEV1/FVC in the experimental group after treatment were higher than those in the control group(all P<0.05).There was no significant difference in the incidence of dry mouth,nausea,dizziness and drowsiness between the experimental group and the control group(all P>0.05).After treatment,serum IL-4 and IL-5 levels in the experimental group were lower than in the control group(all P<0.05).【Conclusion】The combined application of montelukast sodium and budesonide in children with asthma has significant efficacy,effectively improves the level of respiratory indicators in children with asthma,and has good drug safety,which is conducive to alleviating inflammatory reactions.
作者
文福生
戴小萍
莫慧超
WEN Fusheng;DAI Xiaoping;MO Huichao(Department of Pediatrics,Longhua District Central Hospital,Shenzhen,Guangdong 518000,China)
出处
《中国医学工程》
2019年第6期51-54,共4页
China Medical Engineering